{
    "biomarker_id": "AN6683-2",
    "biomarker_canonical_id": "AN6683",
    "condition": {
        "recommended_name": {
            "id": "DOID:263",
            "resource": "Disease Ontology",
            "url": "https://disease-ontology.org/term/DOID:263",
            "name": "kidney cancer",
            "description": "A urinary system cancer that is located_in the kidney."
        },
        "synonyms": [
            {
                "id": "DOID:263",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:263",
                "name": "malignant neoplasm of kidney except pelvis",
                "description": ""
            },
            {
                "id": "DOID:263",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:263",
                "name": "malignant tumour of kidney",
                "description": ""
            },
            {
                "id": "DOID:263",
                "resource": "Disease Ontology",
                "url": "https://disease-ontology.org/term/DOID:263",
                "name": "renal cancer",
                "description": ""
            }
        ],
        "id": "DOID:263"
    },
    "biomarker_component": [
        {
            "biomarker": "increased CD274 level",
            "assessed_biomarker_entity_id": "Q9NZQ7-1",
            "assessed_entity_type": "protein",
            "assessed_biomarker_entity": {
                "recommended_name": "Programmed cell death 1 ligand 1",
                "synonyms": [
                    {
                        "synonym": "B7 homolog 1"
                    },
                    {
                        "synonym": "B7-H1"
                    }
                ]
            },
            "specimen": [
                {
                    "name": "kidney",
                    "namespace": "UBERON",
                    "id": "0002113",
                    "url": "http://purl.obolibrary.org/obo/UBERON_0002113",
                    "loinc_code": ""
                }
            ],
            "evidence_source": [
                {
                    "id": "AN6683-2",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6683-2"
                },
                {
                    "id": "31653140",
                    "database": "PubMed",
                    "url": "https://glygen.org/publication/PubMed/31653140",
                    "tags": [
                        "assessed_biomarker_entity",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "Among the 150 samples, 66 (44%) expressed PDL1 expression in the tumor cell surface, and a significant association was between the PDL1 expression and the high graded tumors"
                        }
                    ]
                },
                {
                    "id": "33797012",
                    "database": "PubMed",
                    "url": "https://glygen.org/publication/PubMed/33797012",
                    "tags": [
                        "assessed_biomarker_entity",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "PD-L1 expression predicts response to immune checkpoint inhibitors in renal cell carcinomas (RCC), but has also been suggested to be linked to poor patient outcome."
                        }
                    ]
                }
            ]
        }
    ],
    "best_biomarker_role": [
        {
            "role": "prognostic"
        }
    ],
    "evidence_source": [
        {
            "id": "AN6683-2",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/AN6683-2"
        },
        {
            "id": "31653140",
            "database": "PubMed",
            "url": "https://glygen.org/publication/PubMed/31653140",
            "tags": [
                "best_biomarker_role",
                " condition"
            ],
            "evidence_list": [
                {
                    "evidence": "Among the 150 samples, 66 (44%) expressed PDL1 expression in the tumor cell surface, and a significant association was between the PDL1 expression and the high graded tumors"
                }
            ]
        },
        {
            "id": "33797012",
            "database": "PubMed",
            "url": "https://glygen.org/publication/PubMed/33797012",
            "tags": [
                "best_biomarker_role",
                " condition"
            ],
            "evidence_list": [
                {
                    "evidence": "PD-L1 expression predicts response to immune checkpoint inhibitors in renal cell carcinomas (RCC), but has also been suggested to be linked to poor patient outcome."
                }
            ]
        }
    ],
    "crossref": [
        {
            "id": "AN6683-2",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/AN6683-2",
            "categories": [
                "Biomarkers"
            ]
        }
    ],
    "citation": [
        {
            "title": "Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.",
            "journal": "Asian Pacific journal of cancer prevention : APJCP",
            "authors": "Chandrasekaran D, Sundaram S, N K, R P",
            "date": "2019",
            "reference": [
                {
                    "type": "PubMed",
                    "id": "31653140",
                    "url": "https://glygen.org/publication/PubMed/31653140"
                }
            ],
            "evidence": [
                {
                    "id": "AN6683-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6683-2"
                }
            ]
        },
        {
            "title": "Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.",
            "journal": "International urology and nephrology",
            "authors": "Moller K, Fraune C, Blessin NC, Lennartz M, Kluth M, Hube-Magg C, Lindhorst L, Dahlem R, Fisch M, Eichenauer T, Riechardt S, Simon R, Sauter G, Buscheck F, Hoppner W, Matthies C, Doh O, Krech T, Marx AH, Zecha H, Rink M, Steurer S, Clauditz TS",
            "date": "2021",
            "reference": [
                {
                    "type": "PubMed",
                    "id": "33797012",
                    "url": "https://glygen.org/publication/PubMed/33797012"
                }
            ],
            "evidence": [
                {
                    "id": "AN6683-2",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6683-2"
                }
            ]
        }
    ],
    "section_stats": [
        {
            "table_id": "biomarker_component",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "biomarker",
                "assessed_biomarker_entity_id",
                "assessed_entity_type",
                "assessed_biomarker_entity.recommended_name"
            ]
        },
        {
            "table_id": "citation",
            "table_stats": [
                {
                    "field": "total",
                    "count": 2
                }
            ],
            "sort_fields": [
                "title",
                "journal",
                "authors",
                "date"
            ]
        }
    ]
}